Girolamo Pelaia

Prof. Girolamo Pelaia

Department of Health Sciences, Università degli studi Magna Graecia di Catanzaro, Catanzaro, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
GPGirolamo Pelaia
Girolamo Pelaia
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
MBMaria Teresa Busceti
Maria Teresa Busceti
Luca GallelliLuca Gallelli
Luca Gallelli
CCCecilia Calabrese
Cecilia Calabrese
RMRosario Maselli
Rosario Maselli
Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the whole spectrum of asthma severity, ranging from mild‐to‐moderate to severe uncontrolled disease, whereas neutrophilic inflammation occurs mostly in more severe asthma. Eosinophilic asthma includes either allergic or nonallergic phenotypes underlying immune responses mediated by T helper (Th)2 cell‐derived cytokines, whilst neutrophilic asthma is mostly dependent on Th17 cell‐induced mechanisms. These immune‐inflammatory profiles develop as a consequence of a functional impairment of T regulatory (Treg) lymphocytes, which promotes the activation of dendritic cells directing the differentiation of distinct Th cell subsets. The recent advances in the knowledge of the cellular and molecular mechanisms underlying asthmatic inflammation are contributing to the identification of novel therapeutic targets, potentially suitable for the implementation of future improvements in antiasthma pharmacologic treatments.

30 November 2012 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
GPGirolamo Pelaia
Girolamo Pelaia
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
RMRosario Maselli
Rosario Maselli

1 January 2020 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
PDF file
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
CTCaterina Tinello
Caterina Tinello
AVAlessandro Vatrella
Alessandro Vatrella
GSGiovambattista De Sarro
Giovambattista De Sarro
GPGirolamo Pelaia
Girolamo Pelaia
The lung is a key target of the cytokine storm that can be triggered by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for the widespread clinical syndrome known as coronavirus disease 2019 (COVID-19). Indeed, in some patients, SARS-CoV-2 promotes a dysfunctional immune response that dysregulates the cytokine secretory pattern. Hypercytokinemia underlies the hyperinflammatory state leading to injury of alveolar epithelial cells and vascular endothelial cells, as well as to lung infiltration sustained by neutrophils and macrophages. Within such a pathogenic context, interleukin-6 (IL-6) and other cytokines/chemokines play a pivotal pro-inflammatory role. Therefore, cytokines and their receptors, as well as cytokine-dependent intracellular signalling pathways can be targeted by potential therapies aimed to relieve the heavy burden of cytokine storm. In particular, the anti-IL-6-receptor monoclonal antibody tocilizumab is emerging as one of the most promising pharmacologic treatments. The reviews of this paper are available via the supplemental material section.

1 January 2018 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
PDF file
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
CCCecilia Calabrese
Cecilia Calabrese
RTRosa Terracciano
Rosa Terracciano
FBFrancesco de Blasio
Francesco de Blasio
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
GPGirolamo Pelaia
Girolamo Pelaia
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinity receptors. Therefore, omalizumab effectively blunts the immune response in atopic asthmatic patients, thus significantly improving the control of asthma symptoms and successfully preventing disease exacerbations. These very positive effects of omalizumab make it possible to drastically decrease both referrals to the emergency room and hospitalizations for asthma exacerbations. Such important therapeutic actions of omalizumab have been documented by several randomized clinical trials, and especially by more than 10 years of real-life experience in daily clinical practice. Omalizumab can also interfere with airway remodelling by inhibiting the activation of IgE receptors located on structural cells such as bronchial epithelial cells and airway smooth muscle cells. Moreover, omalizumab is characterized by a very good safety and tolerability profile. Hence, omalizumab represents a valuable therapeutic option for the add-on biological treatment of severe allergic asthma.

30 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
CCClaudia Crimi
Claudia Crimi
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
CTCaterina Tinello
Caterina Tinello
RTRosa Terracciano
Rosa Terracciano
GPGirolamo Pelaia
Girolamo Pelaia
Asthma is a heterogeneous respiratory disease characterized by usually reversible bronchial obstruction, which is clinically expressed by different phenotypes driven by complex pathobiological mechanisms (endotypes). Within this context, during the last years several molecular effectors and signalling pathways have emerged as suitable targets for biological therapies of severe asthma, refractory to standard treatments. Indeed, various therapeutic antibodies currently allow to intercept at different levels the chain of pathogenic events leading to type 2 (T2) airway inflammation. In addition to pro-allergic immunoglobulin E (IgE), that chronologically represents the first molecule against which an anti-asthma monoclonal antibody (omalizumab) was developed, today other targets are successfully exploited by biological treatments of severe asthma. In particular, pro-eosinophilic interleukin 5 (IL-5) can be targeted by mepolizumab or reslizumab, whereas benralizumab is a selective blocker of IL-5 receptor. Moreover, dupilumab behaves as a dual receptor antagonist of pleiotropic interleukins 4 (IL-4) and 13 (IL-13). Besides these drugs that are already available in medical practice, other biologics are under clinical development such as those targeting innate cytokines, also including the alarmin thymic stromal lymphopoietin (TSLP), which plays a key role in the pathogenesis of type 2 asthma. Therefore, ongoing and future biological therapies are significantly changing the global scenario of severe asthma management. These new therapeutic options make it possible to implement phenotype/endotype-specific treatments, that are delineating personalized approaches precisely addressing the individual traits of asthma pathobiology. Such tailored strategies are thus allowing to successfully target the immune-inflammatory responses underlying uncontrolled T2-high asthma.

10 May 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
CCCecilia Calabrese
Cecilia Calabrese
Alessandro VatrellaAlessandro Vatrella
Alessandro Vatrella
MBMaria Teresa Busceti
Maria Teresa Busceti
EGEugenio Garofalo
Eugenio Garofalo
GPGirolamo Pelaia
Girolamo Pelaia
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).